Musculo-skeletal
Lumiracoxib
Brand: Prexige®
PBAC's latest decision on Lumiracoxib: Recommended with restriction (2005). Considered for Symptomatic treatment of osteoarthritis.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2005 → 2005
Eligible population
patients with symptomatic osteoarthritis
- Therapy area
- Musculo-skeletal
- Line of therapy
- Any
- Evidence base
- RCT
- Primary endpoint
- OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null
- Key trials
- TARGET, CLASS, VIGOR, Trial 0109, Trial 0112, Trial 0128, Trial 0112E
- Comparator
- celecoxib
- Economic model
- Cost-minimisation
- ICER note
- Cost-minimisation analysis used; no ICER calculated
Open on full dashboard →